Atlas Trials

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Clinical trial NCT07142421 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07142421
Sponsor
First Affiliated Hospital of Zhejiang University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma (ESCC)
Start date
2025-08-06
Primary completion
2027-08-31
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.